Navigation Links
Access Pharmaceuticals Presents New Data on ProLindac(TM) at the 2009 AACR Annual Meeting
Date:4/21/2009

- Data demonstrates that ProLindac should provide sustained tumor exposure to platinum and provides a mechanistic rationale for the low hematoxicity observed in the clinic -

DALLAS, April 21 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that its collaborators at Centre Rene Huguenin in France presented new preclinical data on its lead anticancer compound, ProLindac(TM), at the American Association for Cancer Research (AACR) Annual Meeting taking place April 18-22, 2009 at the Colorado Convention Center in Denver. The poster presentation entitled "DACH platinum (dach-Pt) release kinetics, ex-vivo and in vivo plasma protein binding and evaluation of red blood cell (RBC) partitioning of ProLindac, a novel DACH-Pt-bound biopolymer" was presented on Monday, April 20.

ProLindac is Access' novel polymer-based DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access recently announced positive results from the completed phase 2 monotherapy clinical study in recurrent ovarian cancer. The study reported in the 2009 AACR poster provides in vitro and ex-vivo data on the binding of ProLindac to blood components, and suggests a mechanistic rationale for ProLindac's favorable efficacy and safety profile.

"The data shows that ProLindac's polymer carrier is highly bound to circulating plasma proteins," stated David P. Nowotnik, Ph.D., Access' Senior Vice President, Research and Development. "As a result, we would expect ProLindac to provide sustained tumor exposure to platinum. In addition, there was little red blood cell accumulation, which could account for the lower level of hematological toxicities observed for ProLindac compared to others platinum species."

"We are grateful to our European collaborators for their ongoing studies, which continue to expan
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
2. New organic material may speed Internet access
3. Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions
4. GPhA Statement on the Introduction of the Bipartisan Biogenerics Consensus Bill: Promoting Innovation and Access to Life-Saving Medicine Act
5. Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal
6. Campbell Alliance Brand Management Practice to Present at EyeForPharmas Oncology Summit USA and Oncology Market Access Europe Conference
7. Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries
8. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
9. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
10. SurgiQuest Signs a Development and Supply Agreement with Intuitive Surgical for MIS Access Utilizing the AirSeal(TM) Technology
11. Jatropha World 2009 Advance Access: Surprisingly Candid Interview Series Examines Biofuel Predictions Compared to Fossil Fuels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... history lessons often have it that American Indians largely ... chicken pox, influenza and tuberculosis brought to the New ... vary, about 20 million people lived in the Americas ... them were killed by European diseases., But new research ... University and Johannes Krause of the University of Tubingen ...
(Date:8/20/2014)... 2014 Neurotrope, Inc. (OTCQB: NTRP) today ... to provide an update on Company activities. Access ... numbers:(888) 505-4369 (U.S. and Canada) or (719) 325-2315 ... , under "Investor Relations"The teleconference replay will be ... 2, 2014 at (888) 203-1112 (U.S. and ...
(Date:8/20/2014)... 20, 2014  Decision Resources Group finds that the vascular access ... , India and China ... roughly equal to the size of the United States ... will experience much faster growth as a result of strong economic ... Other key findings from Decision Resources Group,s coverage of the BRIC ...
(Date:8/20/2014)... Francisco, CA (PRWEB) August 20, 2014 ... Conference is being held on October 29-30 in ... perspectives from industry, academic and government researchers and clinicians ... in the space. , In the twelve years ... one hundred therapies have been introduced with pharmacogenetic information ...
Breaking Biology Technology:Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3Neurotrope To Host Conference Call 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 36th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2
... company adds new apoAI measurement and apoB/apoAI ratio to ... March 17 /PRNewswire/ -- Atherotech, ... Cholesterol Test in booth #1263 at ACC.09, the American ... The annual meeting takes place March 29-31, 2009, at ...
... Mass., March 17 The pro bono healthcare ... ), has announced that its newly instituted Safe ... Lutheran Health System of La Crosse, Wisconsin. The ... outstanding accomplishments in safe patient handling, safe lifting, ...
... March 17 Cardiorobotics, Inc., a ... use in a wide range of applications, including: ... appointment of Dr. Samuel Straface in the position ... that Dr. Straface has joined Cardiorobotics in this ...
Cached Biology Technology:Atherotech to Exhibit the VAP(R) Cholesterol Test at ACC.09 in Orlando 2Atherotech to Exhibit the VAP(R) Cholesterol Test at ACC.09 in Orlando 3Gundersen Lutheran Health System is Recognized for Safe Lifting Leadership 2Gundersen Lutheran Health System is Recognized for Safe Lifting Leadership 3Cardiorobotics Announces New CEO, PLSG Executive-in-Residence to Lead Company 2Cardiorobotics Announces New CEO, PLSG Executive-in-Residence to Lead Company 3
(Date:8/20/2014)... burning spiciness that is irresistible to some, but intolerable ... using their findings to develop a new drug candidate ... by inflammation or other problems. They reported their progress ... trials, in ACS, Journal of Medicinal Chemistry . ... scientists had pegged a compound called capsaicin as the ...
(Date:8/20/2014)... by researchers at the University of Missouri School of ... life-threatening heart condition caused by muscular dystrophy. , ... Ph.D., the leading author of the study and assistant ... of Molecular Microbiology and Immunology. "This is just a ... a treatment for people with this devastating heart condition, ...
(Date:8/20/2014)... and POINT ROBERTS, Washington , August ... a Key Role in Addressing Security Concerns in the Payment ... global news source covering leading sectors including biometrics, issues commentary ... Jason Peaslee , Managing Partner at Thrive ... Gino Pereira , CEO of NXT-ID, Inc. (OTCBB: NXTD) ...
Breaking Biology News(10 mins):Gene therapy protects mice from lethal heart condition, MU researchers find 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7
... Tampa, Fla. (April 11, 2011) ... be the most efficacious of three kinds of clinically ... in the current issue of Cell Transplantation ... to researchers in Seoul, South Korea, transplantation of PDLSCs ...
... Human umbilical cord blood-derived mensenchymal stem cells (uMSCs) have ... (LN) when transplanted into mouse models of systemic lupus ... immune system aberrations" characterized by diverse clinical conditions, including ... patients with SLE., The beneficial results were reported in ...
... Scientists have moved a step closer to being able to ... technique to map both the connections and functions of nerve ... A new area of research is emerging in the neuroscience ... our genetic make-up, connectomics aims to map the brain,s connections ...
Cached Biology News:Periodontal stem cell transplantation shows promise 2Umbilical cord blood-derived stem cells studied for lupus therapy 2Mapping the brain: New technique poised to untangle the complexity of the brain 2Mapping the brain: New technique poised to untangle the complexity of the brain 3
...
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... types of yeast two-hybrid studies, including complex interaction studies ... Choice of two bait vectors for maximum flexibility and ... Triple reporter strain NMY51 ensures an ... Complete set of controls: pLexA-p53, pLexA-lamin C and ...
Biology Products: